How can that be? A reliable source has told us that TEVA gave up saying that tL was close to approval.
They have. The below comment was said by Shlomo in early August 2010 and included in Tim Anderson's (Sanford Bernstein) analyst report in August 2010 - the analyst report that said tL approval was likely soon. #msg-52989044
Teva President and CEO Shlomo Yanai said last week after presenting second-quarter results that he had good reason to believe his company was close to getting approval for its generic version of Lovenox, but he gave no timeline.
Market Data 
Markets 
AI
